07:37 AM EDT, 05/28/2024 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Tuesday said it has formed a clinical advisory board comprised of clinical research and drug development experts in genetic muscle disorders, including Duchenne muscular dystrophy.

"The formation of this clinical advisory board marks a major development step for Satellos as we continue our evolution in becoming a clinical stage drug development company," said Frank Gleeson, Co-founder and CEO of Satellos. "We believe this will help support Satellos in advancing our lead drug candidate, SAT-3247, as we work to optimize its potential to transform the treatment of Duchenne and serious muscle diseases."

SAT-3247 is an oral small molecule drug designed to target the root cause of muscle loss in degenerative diseases and presents a novel mechanism of action to restore impaired muscle regeneration caused by the absence of functional dystrophin, the company said. Satellos is initially focused in Duchenne muscular dystrophy.